CohBar Inc.
| NASDAQ: CWBR | Healthcare / Biotechnology / USA |
| 0.7850 | +0.1144 | +17.06% | Vol 33.90K | 1Y Perf -60.08% |
| Dec 1st, 2023 15:39 DELAYED |
| BID | 0.00 | ASK | 0.00 | ||
| Open | 0.6706 | Previous Close | 0.6706 | ||
| Pre-Market | - | After-Market | - | ||
| - - | - -% |
| Target Price | 18.00 | Analyst Rating | — 0.00 | |
| Potential % | 2.19K | Finscreener Ranking | — - | |
| Insiders Trans % 3/6/12 mo. | -/-/60 | Value Ranking | — - | |
| Insiders Value % 3/6/12 mo. | -/-/71 | Growth Ranking | — - | |
| Insiders Shares Cnt. % 3/6/12 mo. | -/-/91 | Income Ranking | — - | |
| Price Range Ratio 52W % | 3.24 | Earnings Rating | Neutral | |
| Market Cap | 2.28M | Earnings Date | 14th Nov 2023 | |
| Alpha | -0.05 | Standard Deviation | 0.28 | |
| Beta | 1.89 |
Today's Price Range 0.67061.10 | 52W Range 0.58006.90 | 5 Year PE Ratio Range -10.20-6.90 |
Summary:
Sell
| Technical Indicators: | Neutral |
| Moving Averages: | Strong Sell |
| Performance | |||
|---|---|---|---|
| 1 Week | -28.70% | ||
| 1 Month | -27.11% | ||
| 3 Months | -75.17% | ||
| 6 Months | -75.16% | ||
| 1 Year | -60.08% | ||
| 3 Years | -98.18% | ||
| 5 Years | -99.45% | ||
| 10 Years | - |
| Mngmt Effectiveness | Value | Industry | S&P 500 | US Markets |
|---|---|---|---|---|
ROE (5Y Avg) | -64.57 | |||
ROE last 12 Months | -68.50 | |||
ROA (5Y Avg) | -41.82 | |||
ROA last 12 Months | -62.93 | |||
ROC (5Y Avg) | -81.98 | |||
ROC last 12 Months | -68.97 | |||
Return on invested Capital Q | -12.52 | |||
Return on invested Capital Y | -13.84 | |||
Assets Turnover | 0.00 | |||
Receivables Turnover | 0.00 |
| Valuation | Value | Industry | S&P 500 | US Markets |
|---|---|---|---|---|
| -0.60 | ||||
| 0.33 | ||||
| - | ||||
| - | ||||
| -0.80 | ||||
| -3.69 | ||||
| 0.33 | ||||
| 6.45 | ||||
| -19 688 000.00 | ||||
| Forward PE | -0.23 | |||
| PEG | - |
| Financial Strength | Value | Industry | S&P 500 | US Markets |
|---|---|---|---|---|
| 33.60 | ||||
| 34.80 | ||||
| 0.02 | ||||
| 0.01 | ||||
| -504.00 | ||||
| Leverage Ratio | 1.00 |
| Profitability | Value | Industry | S&P 500 | US Markets |
|---|---|---|---|---|
| - | ||||
| - | ||||
| - | ||||
| - | ||||
| - |
| Revenue | Value | Industry | S&P 500 | US Markets |
|---|---|---|---|---|
| 0.00 | ||||
| 0.00 | ||||
| - | ||||
| - |
| Dividends | Value | Industry | S&P 500 | US Markets |
|---|---|---|---|---|
| - | ||||
| - | ||||
| - | ||||
| - | ||||
| Payout ratio | - |
| Earnings History | Estimate | Reported | Surprise % |
|---|---|---|---|
| Q01 2024 | - | -1.39 | - |
| Q01 2023 | - | -0.75 | - |
| Q04 2022 | - | -1.30 | - |
| Q03 2022 | -1.02 | -0.82 | 19.61 |
| Q02 2022 | -1.20 | -0.90 | 25.00 |
| Q01 2022 | -0.90 | -1.20 | -33.33 |
| Q04 2021 | - | -1.20 | - |
| Q03 2021 | -2.70 | -1.50 | 44.44 |
| Earnings Per End | Estimate | Revision % | Trend |
|---|---|---|---|
| 12/2022 QR | -0.90 | 19.64 | Positive |
| 12/2022 QR | -1.12 | 25.33 | Positive |
| 12/2022 FY | -3.78 | 9.79 | Positive |
| 12/2023 FY | -3.92 | 7.98 | Positive |
| Next Report Date | - |
| Estimated EPS Next Report | - |
| Estimates Count | - |
| EPS Growth Next 5 Years % | - |
| Volume Overview | |
|---|---|
| Volume | 33.90K |
| Shares Outstanding | 2.91K |
| Shares Float | 2.72M |
| Trades Count | 98 |
| Dollar Volume | 29.48K |
| Avg. Volume | 73.88K |
| Avg. Weekly Volume | 102.07K |
| Avg. Monthly Volume | 84.86K |
| Avg. Quarterly Volume | 34.71K |
CohBar Inc. (NASDAQ: CWBR) stock closed at 0.6706 per share at the end of the most recent trading day (a -4.34% change compared to the prior day closing price) with a volume of 124.31K shares and market capitalization of 2.28M. Is a component of indices and it is traded on NASDAQ exchange. The company belongs in the Biotechnology industry, Healthcare sector and employs 10 people. CohBar Inc. CEO is Joseph J. Sarret.
The one-year performance of CohBar Inc. stock is -60.08%, while year-to-date (YTD) performance is -60.43%. CWBR stock has a five-year performance of -99.45%. Its 52-week range is between 0.58 and 6.9, which gives CWBR stock a 52-week price range ratio of 3.24%
CohBar Inc. currently has a PE ratio of -0.60, a price-to-book (PB) ratio of 0.33, a price-to-sale (PS) ratio of -, a price to cashflow ratio of -, a PEG ratio of -, a ROA of -62.93%, a ROC of -68.97% and a ROE of -68.50%. The company’s profit margin is -%, its EBITDA margin is -%, and its revenue ttm is $0.00 , which makes it $0.00 revenue per share.
Of the last four earnings reports from CohBar Inc., there were 1 positive earnings surprise and 0 negative earnings surprise. The company has EPS estimate of $0.00 for the next earnings report. CohBar Inc.’s next earnings report date is -.
The consensus rating of Wall Street analysts for CohBar Inc. is — (0), with a target price of $18, which is +2 192.99% compared to the current price. The earnings rating for CohBar Inc. stock is Neutral (calculated from actual period earnings estimates revision (80% weight) and previous period earnings surprise (20% weight)).
CohBar Inc. has a dividend yield of -% with a dividend per share of $- and a payout ratio of -%.
CohBar Inc. has a Sell technical analysis rating based on Technical Indicators (ADX : 19.71, ATR14 : 0.16, CCI20 : -150.14, Chaikin Money Flow : -0.18, MACD : -0.32, Money Flow Index : 44.49, ROC : -16.80, RSI : 20.12, STOCH (14,3) : 22.10, STOCH RSI : 0.00, UO : 36.15, Williams %R : -77.90), Simple Moving Averages and Exponential Moving Averages.
Aggregated Insider Trades of CohBar Inc. in the last 12-months were:
CohBar Inc.
CohBar Inc is a biotechnology company. It is engaged in the research and development of mitochondria based therapeutics (MBTs) to treat various diseases associated with aging and metabolic dysfunction. The product portfolio of the company includes drug such as CB4209 and CB4211, SHLP-6, SHLP-2 and new MBTs, these address a broad range of age-related diseases, including obesity, fatty liver disease, Type-2 diabetes, cancer, cardiovascular and neurodegenerative diseases. Geographically all the operation of the group is functioned through the region of United States.
CEO: Joseph J. Sarret
Telephone: +1 650 446-7888
Address: 1455 Adams Drive, Menlo Park 94025, CA, US
Number of employees: 10
